2026. PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. Journal of Evidence-Based Medical Research. 2, 03 (Sep. 2026), 58–69. DOI:https://doi.org/10.66687/jebmr.2.03.2026.43.